Harvard Bioscience, Inc. · NASDAQ:HBIO
Harvard Bioscience — Investor Presentation (January 2024)
18 slides from Harvard Bioscience's investor presentation, Jan 5, 2024
Slide 1: HBIO Investor Overview
Jim Green, Chairman , President & CEO January 5, 2024 HBIO Investor Overview Enabling discovery, safety and production of tomorrow’s therapeutics
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward - Looking Statements and Non - GAAP Financial Information Forward - Looking Statements This document contains forward - looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995 . Forward - looking statements may be i
Slide 3: Company profile and balanced portfolio
Most trusted partner of leading academic research institutions, contract research organizations, pharmaceutical and bio - techs in the discovery, production, and safety & regulatory testing of tomorrow’s life - saving therapies PRE - CLINICAL SYSTEMS CELLULAR & MOLECULAR TECHNOLOGIES (CMT) ▪ Academi
Slide 4: Harvard Bioscience Highlights
Harvard Bioscience Highlights Essential, secular growth markets, high barriers, few competitors Growing global marquee customer base High barrier innovative technologies Highly effective sales channel supported by elite applications scientists Strong discipline, lean operating platform DIVERSIFIED C
Slide 5: FY23 reported revenue down slightly from prior year
FY23 reported revenue down slightly from prior year (includes net headwind of $5.1M of discontinued products) FY23 Guidance as Presented November 13 - 14% **** REVENUES ADJUSTED EBITDA & EBITDA MARGINS* FY23 Prelim (unaudited) ** * Non - GAAP measure ; reconciliations to GAAP financial measures are
Slide 6: Today's Global Footprint
Today’s Global Footprint CELLULAR & MOLECULAR AND HBIO HEADQUARTERS Boston PRE - CLINICAL SYSTEMS Minneapolis Sales Office / Small Centers of Excellence Core Operating Site 12 - 31 - 23 12 - 31 - 18 420 547 Employees* 8 14 Sites *Headcount is approximate CELLULAR & MOLECULAR Stuttgart, Germany 6
Slide 7: Market drivers and end market segments
Increased funding for research and development of advanced therapeutics Rising incidence of disease – cardiac, cancer, respiratory, diabetes, obesity, Alzheimer’s, neurological, infectious 1) https://www.researchandmarkets.com/reports/5553406/pharmaceuticals - global - market - report - 2022 - by 2)
Slide 8: Subset of blue-chip recurring customers
Subset of blue - chip recurring customers • Scientific Research labs primarily government & grant funded • Early discovery of new novel drugs and compounds for therapies and vaccines • Advanced cellular testing & gene editing ACADEMIC RESEARCH • Perform early discovery and then transition from disco
Slide 9: Adapt Technologies to High Volume CRO & Bioproduction Applications
9 Adapt Technologies to High Volume CRO & Bioproduction Applications Research & Discovery Pre - Clinical Safety & Toxicology CELLS MOLECULES CLINICAL ORGANOIDS/ ORGANS PRECLINICAL Bio - Production Extend Technology Leadership in Academic Research & Discovery
Slide 10: Strengthen the base and expand high volume apps
• Fortify leadership position and expand recurring revenue in therapy research and pre - clinical testing • Pre - clinical Telemetry and GLP compliant Ponemah data management software for data reporting and analysis • Electroporation/Transfection/ Amino Acid Analysis • Micro - Electrode Arrays (MEAs
Slide 11: Industry leading telemetry, electroporation and MEA platforms
• Gold standard: simultaneous multi - animal wireless telemetry • Full menu offering from smallest to largest animal models • Improved test yields/ reduced cycle time drives customer revenue growth 11 Industry Leading Telemetry & Ponemah Data Management & Reporting Platform Industry Leading Electrop
Slide 12: Expand Higher Volume Industrial Applications: VivaMARS
Ponemah Actimetry Acquisition/Analysis SW Network Router & Switch User‘s computer (local or remote) LAN Value Proposition ▪ Significantly lower operating costs ▪ Significantly reduced test cycle time accelerates revenue ▪ Benchmarked experiment: >2X throughput @ 50 subjects Applications ▪ High throu
Slide 13: BTX Electroporation as a Bridge to Bio-Production
• General Use Cuvettes • In Vitro Coaxial Chambers • Flat Pack Higher Volume Reaction Chambers • Services HBIO IS A PIONEER IN ELECTROP ORATION AND ELECTROFUSION DRIVING NOVEL DISCOVERIES IN DRUG CREATION Electroporation / Electrofusion Consumables & Services • Cell modifications, CAR T - Cell trans
Slide 14: Mesh MEA Organoid Platform
Vision: • Replace/reduce large population early model with In Vitro human/patient testing • Imp rove pre - clinical throughput/yield of successful compounds • Target emerging organoids for neuro and cardio research/discovery • Longer term applications for safety pharmacology & toxicology MOVING TO H
Slide 15: Investment Thesis: Deliver Strong, Profitable, Long-Term Growth
LARGE, LOYAL CUSTOMER BASE IN DRUG RESEARCH & DISCOVERY, SAFETY & REGULATORY, AND BIO - PRODUCTION MARKETS NEW PRODUCT INTRODUCTIONS FOCUSED ON TOP - LINE GROWTH & RECURRING REVENUE Investment Thesis: Deliver Strong, Profitable, Long - Term Growth 15 FOCUSED ON LONG TERM TOPLINE GROWTH WITH 60% GROS
Slide 16: Thank You
Enabling discovery, safety and production of tomorrow’s therapeutics Thank You
Slide 17: Appendix
Appendix 1 7 17
Slide 18: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non - GAAP Financial Measures HARVARD BIOSCIENCE, INC. Reconciliation of GAAP to Non - GAAP Financial Measures (in thousands) Q3 YTD'23 Q3 YTD'22 Year Ended Year Ended Year Ended 30 - Sep - 23 30 - Sep - 22 31 - Dec - 22 31 - Dec - 21 31 - Dec - 20 ($1,597) ($7,850) ($9,516
Harvard Bioscience — Investor Presentation (January 2024) on 6ix